Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Our new book is a comprehensive look at a vital part of medicines development and regulatory affairs. Grab your copy today!
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Your Latest RAPS Member Benefit is here
RAPS is pleased to bring you another edition of its Regulatory Focus Article Series, comprised of timely and relevant technical articles, case studies, interviews, and research reports. These topic-focused collections are intended to benefit RAPS members responsible for healthcare-related products. Articles are developed by global subject-matter experts representing a range of regulatory responsibilities and organizations. These quarterly electronic publications are developed for the benefit of RAPS’ members.
RI is a cornerstone of the regulatory landscape, and evidence-based information and the tools for monitoring and gathering it, are its prized components. RI professionals are regulatory sleuths, key players in pulling together that evidence to shape the policies, legislation, regulations, and guidelines regulators use in strategizing for drug development, approval, and product maintenance. In this series, a number of global regulatory affairs specialists write on aspects of regulatory intelligence that would help product developers stay current with the latest requirements and achieve their development goals in a timely, cost-effective manner.
Inside the Series:
Advanced therapies: Navigation and application of EU and US guidelines during product development
By Kirsten Messmer, PhD, RAC, and Richard Dennett, PhD
FDA warning letters in 2020 reveal concerns around purity and data integrity
By Sarah Tanksley, MS, and Audrey Francis
Regulation of cell and gene therapy products in China
By Yingying Liu, MSc
Current China NMPA clinical pathways for medical device registration
By Grace Fu Palma, MBA, Jason Zhang, MD, Xiaolian Zou, and Beibei Xing, PhD
Regulatory tools for generic drug companies: Formal FDA meetings and controlled correspondence
By Sonal Jagani, MS, RAC
EU regulatory tools for RA professionals
By Maria E. Donawa, MD
US-focused regulatory toolbox: The basics
By Thomas Padula
Starting out: A beginner’s toolkit of US regulatory resources
By Holly Korzendorfer, PhD
Adopting regulatory intelligence strategies to foster the evolving landscape
By Darin S. Oppenheimer, DRSc, FRAPS, RAC, PMP, George A. Cusatis MS, RAC, Jessica L. Hale, PharmD, Jessica Schlegel, MS, and Suraj Ramachandran, MS, RAC
Access more benefits in previous Series on the following topics:
Upcoming for 2021
To access your member benefit, simply login and select the e-Book ‒ RF Article Series: The Shifting Global Regulatory Landscape ‒ in the Member Knowledge Center.
Not a RAPS Member? RAPS’ Membership gives you access to countless resources and a vast network of professional all dedicated to regulatory. Learn More About RAPS Membership and Benefits.